RBR-4b5kzhd尚未招募4 期
Persistence of binding and neutralizing antibodies against SARS-CoV2 strains at 6 months or more after a third dose with recombinant covid-19 vaccine (AstraZeneca/Fiocruz), mRNA covid-19 vaccine (Comirnaty, Pfizer/ Wyeth), recombinant covid-19 vaccine (Janssen) or adsorbed inactivated Covid-19 vaccine Coronavac (Sinovac/ Butantan) in subjects primed with two Sinovac/Butantan doses – extension of study RHH_001 and assessment of safety and immunogenicity of 4th dose with recombinant covid-19 vaccine (AstraZeneca/Fiocruz) or mRNA covid-19 vaccine (Comirnaty, Pfizer/ Wyeth)
适应症
试验速览
- 阶段
- 4 期
- 状态
- 尚未招募
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Intervention
入排标准
- 年龄范围
- 0 至 0（—）
入选标准
- •Participants in study RHH 001 per protocol population who were fully evaluable. Those participants included in previous neutralization assay subsets will be targeted for enrolment first if operationally feasible; Subjects willing and able to provide informed consent prior to any study procedure; Participants willing and able to comply with the study procedure; Subjects who had received heterologous or homologous third vaccine dose 6 months or more prior to this study. For part 2 in addition: nformed consent to receive 4 th vaccine dose, AstraZeneca/Fiocruz or Pfizer/Wyeth; No contraindication against AstraZeneca/ Fiocruz or Pfizer/ Wyeth SARSC0V2 vaccine; For females of childbearing potential: willingness to practice continuous effective contraception during the study and a negative pregnancy test on the days on day of vaccination.
排除标准
- •Any additional SARSCoV2 vaccine after the 3rd dose in study RHH 001. For part 2 in addition: Participants with a history of serious vaccine-related adverse reaction or serious allergic reaction (e.g., anaphylaxis) to any study vaccine component, as described in the last summary of product characteristics for AstraZeneca/Fiocruz or Pfizer/Wyeth; Participants with a known bleeding disorder that, in the investigator’s opinion, would contraindicate intramuscular injection; Participants with any progressive or serious neurological disorder, seizure disorder or history of Guillian-Barré syndrome; Participants given treatment with immunosuppressant therapy within the last 90 days, including cytotoxic agents or systemic corticosteroids or planned receipt during the study period. If a short-term cycle of immunosuppressant systemic corticosteroid dose has been used to treat acute disease, the participant should not be enrolled in the study until corticosteroid therapy has been discontinued for at least 15 days prior to the first study vaccination. In case the participant has been on an immunosuppressant dose of a depot, intramuscular or intra-articular corticosteroid, 60 days should be waited for their enrolment in the study. Inhaled/nebulized, intra-articular, intrabursal or topical (skin or eyes) corticosteroids are allowed; Participants with autoimmune diseases, other than: Hashimoto thyroiditis, vitiligo, psoriasis, discoid lupus and the like; HIV positive participants and/or in treatment for HIV; Participants given any other investigational product within the 30 days prior to administration of 4th dose or who intend to take part in another clinical trial at any time during this study conduction; Participants given any other licensed vaccine within 14 days prior to enrolment in this study or who plan to receive any vaccine up to 28 days after vaccination; Participants given treatment with Rituximab or any other anti CD20 monoclonal antibody within 9 months prior to administration of 4 th dose or planned during the study period; Administration of intravenous immunoglobulins and/or any blood products within 3 months prior to enrolment or planned dosing during the study period; Participants with any condition that, in the investigator’s opinion, could interfere with the status primary objectives or represent an additional risk for the participant. Temporary exclusion criteria for both Part 1 and Part 2: Participants with a recent history of COVID19 (minor 4 weeks prior to visit 1) will be delayed until 4 weeks after diagnosis; Participants with fever major 37.5 °C (axillary) or any acute disease at baseline (Day 1) or within the 3 days prior to randomization. Febrile participants with mild diseases may be enrolled at the investigator’s discretion once fever has resolved.
研究者
相似试验
进行中（未招募）
4 期
Evaluating the persistence of protection of a 3rd dose of COVID vaccine and the safety and induced protection of a 4th dose of COVID-19 vaccines in previously vaccinated adultsISRCTN12022293niversity of Oxford1,168
招募中
不适用
The seroprevalence of neutralizing antibody against Japanese encephalitis virus in health care workersJapanese encephalitis riskJapanese encephalitisSeroprevalenceSeroepidemiologySerological studyBangkokadultshealthcare workersThailandTCTR20151017004Sanofi Pasteur, Thailand400
Enrolling By Invitation
不适用
The seroprevalence of neutralizing antibody against Dengue virus in health care workersDengue fever riskDenguePRNTNeutralizing antibodySeroprevalenceSeroepidemiologySerological studyBangkokadultshealthcare workersThailandTCTR20160303002Sanofi Pasteur, Thailand402
进行中（未招募）
不适用
Persistence of antibodies at 3, 4 and 6 years of age after vaccination with meningococcal, pneumococcal and Hib vaccinesHealthy volunteers (prevention of invasive diseases caused by Haemophilus influenzae (type b) and Neisseria meningitidis serogroup C)MedDRA version: 14.1Level: LLTClassification code 10027275Term: Meningococcal infection, unspecifiedSystem Organ Class: 10021881 - Infections and infestationsMedDRA version: 14.1Level: PTClassification code 10069533Term: Haemophilus influenzae type b immunisationSystem Organ Class: 10042613 - Surgical and medical proceduresEUCTR2008-007846-69-DEGlaxoSmithKline Biologicals581
招募中
4 期
Antibody persistence against diphtheria, tetanus, pertussis, hepatitis B, measles, mumps and rubella in 5-8-year-old Thai children following primary and first booster immunization with pentavalent vs. hexavalent vaccinesVaccine immunogenicitydiphtheria toxoid, tetanus toxoid, aellular pertussis , whole-cell pertussis, mealses, mumps, rubella, hepatitis B. childrenTCTR20231017001ational Reserach Council of Thailand (NRCT)200